


# Discover & Deliver: Lilly Begins the World's First Study of a Potential COVID-19 Antibody Treatment

Fully reopening the world economy is dependent on discovering safe and effective vaccines and treatments for coronavirus. As of today, there are [over 320 vaccines and treatments in development](#) to combat COVID-19.



While industry, academic institutions, and the government continue to collaborate at an unprecedented speed to develop a vaccine, scientists across the research community have also joined forces to develop another type of treatment to combat the virus: antibody therapies.

As one of the world's leading biopharmaceutical companies, Eli Lilly and Company is dedicating its significant scientific prowess and medical expertise to attack COVID-19. On June 1, the company announced that it started the [world's first study in humans](#) of a potential antibody treatment to fight COVID-19 infections.

Lilly believes the investigational medicine, LY-CoV555, holds promise because antibody therapies are designed specifically to attack the coronavirus. They may be particularly important for groups hardest hit by the disease, such as the elderly and those with compromised immune

systems.

Lilly scientists developed the antibody in just three months after Lilly's partner AbCellera and the Vaccine Research Center at the National Institute of Allergy and Infectious Diseases (NIAID) identified it from a blood sample taken from one of the first U.S. patients who recovered from COVID-19.

Should Phase 1 results show the antibody can be safely administered, Lilly expects to move into the next phase of testing, studying LY-CoV555 in non-hospitalized COVID-19 patients and in preventative settings with vulnerable patient populations. The company also has a second potential antibody therapy in development.

Following the announcement of the Phase 1 trial, Daniel Skovronsky, M.D., Ph.D., Lilly's Chief Scientific Officer and president of Lilly Research Laboratories stated, "We are grateful to collaborate with colleagues at AbCellera, NIAID, and the many academic institutions who have helped us reach this milestone in humanity's fight against COVID-19 — a disease first characterized only six months ago. We are privileged to help usher in this new era of drug development."

—Jonathan Weinberger, Executive Vice President, U.S. Chamber's Global Innovation Policy Center

